NEW YORK (GenomeWeb News) – Sequenom today said second-quarter net loss narrowed on a 15-percent increase in revenues and reduced R&D spending.
The results caused shares in the company to trade up 6.9  percent, or $.11, at $1.70 mid-afternoon today.
Receipts for the three months ended June 30 increased to $7 million from $6 million year over year.
R&D costs declined almost 20 percent to $2.4 million from $3 million from the comparable quarter a year ago.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.